The METTL3-m6A Epitranscriptome: Dynamic Regulator of Epithelial Development, Differentiation, and Cancer

• Published in: Genes Vol. 12; no. 7; p. 1019
• Main Authors: Maldonado López, Alexandra, Capell, Brian C.
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 30.06.2021; MDPI
• Subjects: Binding sites; Chromatin; Clinical trials; DNA damage; DNA methylation; Epigenetics; epithelial; epitranscriptomics; Gene expression; Gene regulation; Localization; m6A; Mammals; Methyltransferase; METTL3; N6-methyladenosine; Proteins; Review; RNA; RNA polymerase; Squamous cell carcinoma; Transcription factors; Transfer RNA; Writers
• ISSN: 2073-4425; 2073-4425
• DOI: 10.3390/genes12071019

Dynamic modifications on RNA, frequently termed both, “RNA epigenetics” and “epitranscriptomics”, offer one of the most exciting emerging areas of gene regulation and biomedicine. Similar to chromatin-based epigenetic mechanisms, writers, readers, and erasers regulate both the presence and interpretation of these modifications, thereby adding further nuance to the control of gene expression. In particular, the most abundant modification on mRNAs, N6-methyladenosine (m6A), catalyzed by methyltransferase-like 3 (METTL3) has been shown to play a critical role in self-renewing somatic epithelia, fine-tuning the balance between development, differentiation, and cancer, particularly in the case of squamous cell carcinomas (SCCs), which in aggregate, outnumber all other human cancers. Along with the development of targeted inhibitors of epitranscriptomic modulators (e.g., METTL3) now entering clinical trials, the field holds significant promise for treating these abundant cancers. Here, we present the most current summary of this work, while also highlighting the therapeutic potential of these discoveries.